MaxCyte (MXCT) Set to Announce Earnings on Tuesday

MaxCyte (NASDAQ:MXCT - Get Free Report) is scheduled to be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect MaxCyte to post earnings of ($0.14) per share for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.

MaxCyte (NASDAQ:MXCT - Get Free Report) last released its quarterly earnings results on Tuesday, March 12th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.05. MaxCyte had a negative return on equity of 15.90% and a negative net margin of 91.85%. The company had revenue of $15.67 million for the quarter, compared to analyst estimates of $15.60 million. On average, analysts expect MaxCyte to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Trading Down 0.8 %

Shares of NASDAQ:MXCT traded down $0.03 during trading on Tuesday, hitting $3.63. 516,032 shares of the company's stock traded hands, compared to its average volume of 622,491. The company has a 50-day moving average price of $4.17 and a 200-day moving average price of $4.35. MaxCyte has a 52 week low of $2.45 and a 52 week high of $5.55. The company has a market cap of $378.97 million, a price-to-earnings ratio of -9.81 and a beta of 1.34.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MXCT. William Blair reiterated an "outperform" rating on shares of MaxCyte in a report on Wednesday, March 13th. BTIG Research reduced their target price on shares of MaxCyte from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, March 13th. Finally, Stephens reissued an "overweight" rating and issued a $11.00 price target on shares of MaxCyte in a research note on Tuesday, April 23rd.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.